Online citations, reference lists, and bibliographies.
← Back to Search

Multiomics Profiling Establishes The Polypharmacology Of FDA-Approved CDK4/6 Inhibitors And The Potential For Differential Clinical Activity.

M. Hafner, Caitlin E. Mills, Kartik Subramanian, C. Chen, M. Chung, Sarah A. Boswell, Robert A. Everley, Changchang Liu, C. Walmsley, D. Juric, P. Sorger
Published 2019 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The target profiles of many drugs are established early in their development and are not systematically revisited at the time of FDA approval. Thus, it is often unclear whether therapeutics with the same nominal targets but different chemical structures are functionally equivalent. In this paper we use five different phenotypic and biochemical assays to compare approved inhibitors of cyclin-dependent kinases 4/6-collectively regarded as breakthroughs in the treatment of hormone receptor-positive breast cancer. We find that transcriptional, proteomic, and phenotypic changes induced by palbociclib, ribociclib, and abemaciclib differ significantly; abemaciclib in particular has advantageous activities partially overlapping those of alvocidib, an older polyselective CDK inhibitor. In cells and mice, abemaciclib inhibits kinases other than CDK4/6 including CDK2/cyclin A/E-implicated in resistance to CDK4/6 inhibition-and CDK1/cyclin B. The multifaceted experimental and computational approaches described here therefore uncover underappreciated differences in CDK4/6 inhibitor activities with potential importance in treating human patients.
This paper references
10.1126/science.aan4368
The target landscape of clinical kinase drugs
Susan Klaeger (2017)
10.1021/ac502040v
MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes
G. McAlister (2014)
10.1038/nmeth.1714
MS3 eliminates ratio distortion in isobaric labeling-based multiplexed quantitative proteomics
Lily Ting (2011)
10.2147/OTT.S250619
Identification of Aurora Kinase A as a Biomarker for Prognosis in Obesity Patients with Early Breast Cancer
Junhan Jiang (2020)
10.1038/nprot.2007.261
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips
J. Rappsilber (2007)
10.1038/s41467-020-16559-0
Quantifying CDK inhibitor selectivity in live cells
C. Wells (2020)
10.18632/ONCOTARGET.2270
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
J. Franco (2014)
10.1038/nbt1240
A probability-based approach for high-throughput protein phosphorylation analysis and site localization
S. Beausoleil (2006)
10.1038/nmeth.4220
Power Analysis of Single Cell RNA-Sequencing Experiments
Valentine Svensson (2017)
10.1158/1538-7445.AM2016-2830
Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6
T. Burke (2016)
10.1101/151738
A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours
Jia-Ren Lin (2017)
10.1038/nbt.3882
Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics
M. Hafner (2017)
10.1007/s10637-014-0120-7
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert (2014)
10.1200/JCO.2016.34.15_SUPPL.510
MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.
M. Dickler (2016)
10.1126/science.1132939
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
J. Lamb (2006)
10.1038/onc.2010.154
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean (2010)
10.1093/nar/gkr1122
PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse
P. Hornbeck (2012)
10.1158/1535-7163.MCT-16-0300
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
P. Chen (2016)
10.1158/0008-5472.CAN-15-0728
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
M. T. Herrera-Abreu (2016)
10.1101/003236
Characterization of directed differentiation by high-throughput single-cell RNA-Seq
Magali Soumillon (2014)
10.1021/ac301572t
Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses.
G. McAlister (2012)
10.1200/JCO.18.00925
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
N. Turner (2019)
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
D. Fry (2004)
10.1038/nrc4000
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
C. Caunt (2015)
10.1021/ac201894j
Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments.
A. Kettenbach (2011)
10.1002/pmic.201400154
Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10‐plex quantitative proteomics and phosphoproteomics
J. Paulo (2015)
10.1038/s41589-018-0081-9
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Hayley J. Donnella (2018)
10.7554/eLife.44571
Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation
H. W. Yang (2020)
10.1002/cpch.19
Designing Drug‐Response Experiments and Quantifying their Results
M. Hafner (2017)
10.1021/acs.biochem.6b00629
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
T. Nomanbhoy (2016)
10.1158/2159-8290.CD-16-0095
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
A. Patnaik (2016)
10.1038/nbt1068
A small molecule–kinase interaction map for clinical kinase inhibitors
M. Fabian (2005)
10.1158/1541-7786.MCR-17-0468
Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
E. Cousins (2017)
10.1038/nmeth.2968
KinomeXplorer: an integrated platform for kinome biology studies
Heiko Horn (2014)
10.1158/2159-8290.CD-16-0563
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
J. Lim (2016)
10.1016/j.breast.2016.07.015
The genomic landscape of breast cancer and its interaction with host immunity.
S. Luen (2016)
10.1038/nbt.2017
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis (2011)
Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
S. Wittmann (2003)
10.18632/oncotarget.17778
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Raquel Torres-Gúzman (2017)
10.1016/1044-0305(94)80016-2
An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database
J. Eng (1994)
10.1158/1538-7445.AM2014-4756
Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer
N. O’Brien (2014)
10.1021/JM049354H
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
P. Toogood (2005)
10.1126/science.1254721
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
A. Crystal (2014)
10.1016/j.ajpath.2013.08.009
Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells.
Nancy Palechor-Ceron (2013)
10.1182/BLOOD.V96.2.393.014K47_393_397
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
S. Kitada (2000)
10.1158/2159-8290.CD-13-0286
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
J. Balko (2014)
10.1038/nrd4504
The history and future of targeting cyclin-dependent kinases in cancer therapy
U. Asghar (2015)
10.1093/nar/gkw377
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
M. Kuleshov (2016)
10.1038/nmeth.3853
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
M. Hafner (2016)
10.1038/nrclinonc.2016.26
Treating cancer with selective CDK4/6 inhibitors
B. O'Leary (2016)
10.1038/onc.2016.379
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang (2017)
10.1158/1535-7163.MCT-17-0290
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
N. O’Brien (2018)
10.18632/oncotarget.26215
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Sunkyu Kim (2018)
10.1101/151738
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes
Jia-Ren Lin (2018)
10.1093/nar/gks042
Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation
Davis J. McCarthy (2012)
10.1038/nbt0517-395
Astex shapes CDK4/6 inhibitor for approval
M. Peplow (2017)
10.1038/sj.onc.1210414
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
S. Meloche (2007)
10.1200/JCO.2017.73.7585
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
G. Sledge (2017)
10.1186/bcr2419
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
R. Finn (2009)
10.1021/acs.analchem.5b04123
Phosphoproteomics in the Age of Rapid and Deep Proteome Profiling
N. M. Riley (2016)
10.1200/JCO.2017.73.9375
Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
J. Griggs (2017)
10.1056/NEJMOA1609709
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
G. Hortobagyi (2016)
10.1093/bioinformatics/btw277
RapMap: a rapid, sensitive and accurate tool for mapping RNA-seq reads to transcriptomes
A. Srivastava (2016)
10.1158/1078-0432.CCR-17-0369
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
U. Asghar (2017)
10.1073/pnas.0506580102
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Aravind Subramanian (2005)
10.1021/cb500135f
An Inhibitor’s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States
A. Echalier (2014)
10.1158/2159-8290.CD-15-0894
Targeting CDK4 and CDK6: From Discovery to Therapy.
C. Sherr (2016)
10.1038/nature10098
Global quantification of mammalian gene expression control
Björn Schwanhäusser (2011)
10.1073/pnas.1120985109
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression
J. Drake (2012)
First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.
J. Mccain (2015)
10.1093/bioinformatics/btp616
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
M. Robinson (2010)
10.1016/j.ccell.2016.02.006
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
S. Goel (2016)
Authentication of Human Cell Lines by STR DNA Profiling Analysis -- Assay Guidance Manual
Sittampalam Gs (2004)
10.18632/oncotarget.18435
Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
E. Knudsen (2017)
10.18632/oncotarget.27539
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
Lacey M. Litchfield (2020)
10.1186/s12885-020-06728-1
A key genomic signature associated with lymphovascular invasion in head and neck squamous cell carcinoma
J. Zhang (2020)
10.1016/S1470-2045(15)00613-0
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
M. Cristofanilli (2016)
10.1021/acschembio.5b00368
Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
N. J. Sumi (2015)
10.1124/dmd.114.062745
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub (2015)
10.1021/pr5012608
Optimized chemical proteomics assay for kinase inhibitor profiling.
Guillaume Médard (2015)
10.1016/j.cell.2012.02.053
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
J. Duncan (2012)



This paper is referenced by
10.7554/eLife.44571
Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation
H. W. Yang (2020)
10.3390/cancers13010006
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
Silvia La Monica (2020)
10.1101/2020.12.03.408500
An Integrated Clinical, Omic, and Image Atlas of an Evolving Metastatic Breast Cancer
B. Johnson (2020)
10.1038/s41388-020-1354-9
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Verena Wagner (2020)
10.1101/2020.02.26.966689
Drug GRADE: an integrated analysis of population growth and cell death reveals drug-specific and cancer subtype-specific response profiles
Hannah R. Schwartz (2020)
10.1101/2020.05.15.098749
Machine Learning Identifies Novel Candidates for Drug Repurposing in Alzheimer’s Disease
S. Rodriguez (2020)
10.1016/j.celrep.2020.107800
Drug GRADE: An Integrated Analysis of Population Growth and Cell Death Reveals Drug-Specific and Cancer Subtype-Specific Response Profiles
Hannah R. Schwartz (2020)
10.1080/17460441.2020.1767063
An up-to-date overview of computational polypharmacology in modern drug discovery
Rajan Chaudhari (2020)
10.3390/ph13120418
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Lisa Scheiblecker (2020)
10.1186/s13058-019-1230-0
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
H. Patel (2019)
10.3390/ijms21176350
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
R. Roncato (2020)
10.1186/s12885-020-06728-1
A key genomic signature associated with lymphovascular invasion in head and neck squamous cell carcinoma
J. Zhang (2020)
10.1158/1535-7163.MCT-19-0253
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Scott Schoninger (2020)
10.1007/s40259-019-00382-1
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications
M. Santoni (2019)
10.1016/j.cels.2020.09.003
Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials.
Adam C. Palmer (2020)
10.2147/OTT.S250619
Identification of Aurora Kinase A as a Biomarker for Prognosis in Obesity Patients with Early Breast Cancer
Junhan Jiang (2020)
10.1016/j.phrs.2020.104686
A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB.
Qing-Yun Chong (2020)
10.1007/s11912-020-00917-8
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Jing Xi (2020)
10.3390/cancers12123597
Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
Muh-Lii Liang (2020)
10.3390/molecules25215199
Discovery of 12O—A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor
Yan Fan (2020)
10.1080/14756366.2019.1705290
Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control
X. Wang (2020)
10.1101/401620
Comparing the efficacy of cancer therapies between subgroups in basket trials
Adam C. Palmer (2018)
10.1098/rsob.200200
Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture
E. Trotter (2020)
10.1038/s41467-020-16559-0
Quantifying CDK inhibitor selectivity in live cells
C. Wells (2020)
10.1002/med.21769
How selective are clinical CDK4/6 inhibitors?
D. Hendrychová (2020)
10.18632/oncotarget.27539
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
Lacey M. Litchfield (2020)
10.1101/2020.06.03.130864
Multi-Omic Analysis Reveals Disruption of Cholesterol Homeostasis by Cannabidiol in Human Cell Lines
S. Guard (2020)
10.1634/theoncologist.2019-0551
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
P. Kaufman (2019)
10.1101/2020.07.04.187625
Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronised cell cycle progression in human cell culture
Eleanor Wendy Trotter (2020)
10.1101/2020.07.04.187625
Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronised cell cycle progression in human cell culture
W. Trotter (2020)
Semantic Scholar Logo Some data provided by SemanticScholar